{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:55:59Z","timestamp":1782334559686,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T00:00:00Z","timestamp":1270684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00280-010-1317-x","type":"journal-article","created":{"date-parts":[[2010,4,7]],"date-time":"2010-04-07T13:13:24Z","timestamp":1270646004000},"page":"413-423","source":"Crossref","is-referenced-by-count":60,"title":["Bendamustine: something old, something new"],"prefix":"10.1007","volume":"66","author":[{"given":"Nishant","family":"Tageja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasdeepa","family":"Nagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,8]]},"reference":[{"issue":"17","key":"1317_CR1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1001\/jama.1984.03340410063036","volume":"251","author":"LS Goodman","year":"1984","unstructured":"Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT (1984) Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA 251(17):2255\u20132261","journal-title":"JAMA"},{"issue":"2 Suppl","key":"1317_CR2","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/1097-0142(197808)42:2+<932::AID-CNCR2820420716>3.0.CO;2-2","volume":"42","author":"GP Canellos","year":"1978","unstructured":"Canellos GP, Lister TA, Skarin AT (1978) Chemotherapy of the non-Hodgkin\u2019s lymphomas. Cancer 42(2 Suppl):932\u2013940","journal-title":"Cancer"},{"key":"1317_CR3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"1317_CR4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/annonc\/mdi098","volume":"16","author":"P Boyle","year":"2005","unstructured":"Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481\u2013488","journal-title":"Ann Oncol"},{"key":"1317_CR5","first-page":"11","volume":"25","author":"RC Young","year":"1988","unstructured":"Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25:11\u201316","journal-title":"Semin Hematol"},{"key":"1317_CR6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced- stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet 362:516\u2013522","journal-title":"Lancet"},{"key":"1317_CR7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J et al (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441\u2013449","journal-title":"N Engl J Med"},{"key":"1317_CR8","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"OW Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM et al (2006) Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143\u20134149","journal-title":"J Clin Oncol"},{"key":"1317_CR9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Storer B, Maris M, Sorror ML, Agura E et al (2008) Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:211\u2013217","journal-title":"J Clin Oncol"},{"issue":"8","key":"1317_CR10","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27(8):1202\u20131208","journal-title":"J Clin Oncol"},{"issue":"8","key":"1317_CR11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-L\u00f3pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825\u20132833","journal-title":"J Clin Oncol"},{"key":"1317_CR12","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cylophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"1317_CR13","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V108.11.481.481","volume":"108","author":"RE Marcus","year":"2006","unstructured":"Marcus RE, Solal-Celigny P, Imrie K et al (2006) MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin\u2019s lymphoma (NHL). Blood 108:146a abstr 481","journal-title":"Blood"},{"issue":"6","key":"1317_CR14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/10428190902878471","volume":"50","author":"C Stolz","year":"2009","unstructured":"Stolz C, Schuler M (2009) Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma 50(6):873\u2013885","journal-title":"Leuk Lymphoma"},{"key":"1317_CR15","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI et al (2002) Treatment with ibritumomabtiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:3262\u20133269","journal-title":"J Clin Oncol"},{"key":"1317_CR16","first-page":"1013","volume":"110","author":"W Ozegowski","year":"1971","unstructured":"Ozegowski W, Krebs D (1971) IMET 3393, (-[1-Methyl-5-bis-(\u03b2-chloroethyl)-amino-benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds [in German]. Zbl Pharm 110:1013\u20131019","journal-title":"Zbl Pharm"},{"key":"1317_CR17","volume-title":"Treanda (bendamustine hydrochloride for injection) for intravenous infusion: US prescribing information","author":"Cephalon, Inc.","year":"2008","unstructured":"Cephalon, Inc. (2008) Treanda (bendamustine hydrochloride for injection) for intravenous infusion: US prescribing information. Cephalon, Inc, Frazer"},{"key":"1317_CR18","unstructured":"Cephalon (2008) Cephalon receives FDA approval for Treanda to treat patients with relapsed indolent non-Hodgkin\u2019s lymphoma [media release]. 2008 Oct 31 [online]. Available from URL: http:\/\/www.cephalon.com\/media\/news-releases\/"},{"issue":"4 Suppl 13","key":"1317_CR19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","volume":"29","author":"V Gandhi","year":"2002","unstructured":"Gandhi V (2002) Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 29(4 Suppl 13):4\u201311","journal-title":"Semin Oncol"},{"key":"1317_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309\u2013317","journal-title":"Clin Cancer Res"},{"key":"1317_CR21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0005-2787(72)90282-1","volume":"287","author":"M Hartmann","year":"1972","unstructured":"Hartmann M, Zimmer C (1972) Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393, and 3943. Biochim Biophys Acta 287:386\u2013389","journal-title":"Biochim Biophys Acta"},{"key":"1317_CR22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D, Harstrick A, Doll K et al (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7:415\u2013421","journal-title":"Anticancer Drugs"},{"key":"1317_CR23","first-page":"640a","volume":"102","author":"LM Leoni","year":"2003","unstructured":"Leoni LM, Bailey B, Reifert J (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood 102:640a abstr 2363","journal-title":"Blood"},{"key":"1317_CR24","first-page":"485","volume":"86","author":"KU Chow","year":"2001","unstructured":"Chow KU, Boehrer S, Geduldig K et al (2001) In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin\u2019s lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 86:485\u2013493","journal-title":"Haematologica"},{"key":"1317_CR25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.34873","volume":"29","author":"MJ Rummel","year":"2002","unstructured":"Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E (2002) In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol 29:12\u201314","journal-title":"Semin Oncol"},{"key":"1317_CR26","doi-asserted-by":"crossref","first-page":"229b","DOI":"10.1182\/blood.V104.11.4580.4580","volume":"104","author":"S Kanekal","year":"2004","unstructured":"Kanekal S, Crain B, Elliott G (2004) SDX-105 (TreandaTM) enhances the tumor growth inhibitory effect of rituximab in Daudi lymphoma xenografts. Blood 104:229b abstr 4580","journal-title":"Blood"},{"key":"1317_CR27","first-page":"33","volume":"87","author":"KU Chow","year":"2002","unstructured":"Chow KU, Sommerlad WD, Boehrer S et al (2002) Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87:33\u201343","journal-title":"Haematologica"},{"key":"1317_CR28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CAD.0b013e3280149eb1","volume":"18","author":"M Rasschaert","year":"2007","unstructured":"Rasschaert M, Schrijvers D, Van den Brande J et al (2007) A phase I study of bendamustine hydrochloride administered once every 3\u00a0weeks in patients with solid tumors. Anticancer Drugs 18:587\u2013595","journal-title":"Anticancer Drugs"},{"key":"1317_CR29","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.bjc.6603776","volume":"96","author":"M Rasschaert","year":"2007","unstructured":"Rasschaert M, Schrijvers D, Van den Brande J et al (2007) A phase I study of bendamustine hydrochloride administered day 1\u00a0+\u00a02 every 3\u00a0weeks in patients with solid tumors. Br J Cancer 96:1692\u20131698","journal-title":"Br J Cancer"},{"key":"1317_CR30","unstructured":"Matthias M, Preiss R, Sohr R, et al. (1995) Pharmacokinetics of bendamustine in patients with malignant tumors [abstract no. 1476]. 31st Annual Meeting of the American Society of Clinical 2008 Nov 4] Oncology; Los Angeles (CA); 14:458"},{"key":"1317_CR31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-006-0331-5","volume":"59","author":"J Teichert","year":"2007","unstructured":"Teichert J, Baumann F, Chao Q et al (2007) Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 59:759\u2013770","journal-title":"Cancer Chemother Pharmacol"},{"key":"1317_CR32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1124\/dmd.105.003624","volume":"33","author":"J Teichert","year":"2005","unstructured":"Teichert J, Sohr R, Baumann F et al (2005) Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Disp 33:984\u2013992","journal-title":"Drug Metab Disp"},{"key":"1317_CR33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s004320050225","volume":"124","author":"K H\u00f6ffken","year":"1998","unstructured":"H\u00f6ffken K, Merkle K, Sch\u00f6nfelder M et al (1998) Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 124:627\u2013632","journal-title":"J Cancer Res Clin Oncol"},{"key":"1317_CR34","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1008309911008","volume":"11","author":"P Sch\u00f6ffski","year":"2000","unstructured":"Sch\u00f6ffski P, Seeland G, Engel H et al (2000) Weekly administration of bendamustine: a phase I study in patients with advanced progresive solid tumors. Ann Oncol 11:729\u2013734","journal-title":"Ann Oncol"},{"key":"1317_CR35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/PL00008463","volume":"126","author":"P Sch\u00f6ffski","year":"2000","unstructured":"Sch\u00f6ffski P, Hagedorn T, Gr\u00fcnwald V et al (2000) Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumors. J Cancer Res Clin Oncol 126:41\u201347","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1317_CR36","first-page":"S54","volume":"83","author":"JS Owen","year":"2008","unstructured":"Owen JS, Melhem M, D\u2019Andrea D et al (2008) Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin\u2019s lymphoma (NHL). Pharmacol Ther 83(1):S54\u2013S55","journal-title":"Pharmacol Ther"},{"key":"1317_CR37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","volume":"12","author":"A Heider","year":"2001","unstructured":"Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Anticancer Drugs 12:725\u2013729","journal-title":"Anticancer Drugs"},{"key":"1317_CR38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","volume":"128","author":"K Bremer","year":"2002","unstructured":"Bremer K (2002) High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin\u2019s lymphomas. J Cancer Res Clin Oncol 128:603\u2013609","journal-title":"J Cancer Res Clin Oncol"},{"key":"1317_CR39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L et al (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26:204\u2013210","journal-title":"J Clin Oncol"},{"key":"1317_CR40","doi-asserted-by":"crossref","unstructured":"Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD (2009) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study Cancer","DOI":"10.1002\/cncr.24714"},{"key":"1317_CR41","first-page":"671","volume":"44","author":"K Ruffert","year":"1989","unstructured":"Ruffert K, Jann H, Syrbe G et al (1989) Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin\u2019s lymphoma. Z Klin Med 44:671\u2013674","journal-title":"Z Klin Med"},{"issue":"Suppl 11","key":"1317_CR42","first-page":"S149","volume":"77","author":"K Blumenstengel","year":"1998","unstructured":"Blumenstengel K, Fricke HJ, Kath R et al (1998) Bendamustine (B), vincristine (O), prednisone (P) in relapsed and refractory low grade non-Hodgkin\u2019s lymphoma (NHL) [abstract]. Ann Hematol 77(Suppl 11):S149","journal-title":"Ann Hematol"},{"issue":"3","key":"1317_CR43","first-page":"125","volume":"10","author":"M Herold","year":"1999","unstructured":"Herold M, Schulze A, Mantovani L et al (1999) BOP versus COP in advanced low-grade non-Hodgkin\u2019s lymphoma\u2013results of a randomized multicenter trial [abstract]. Ann Oncol 10(3):125","journal-title":"Ann Oncol"},{"key":"1317_CR44","first-page":"171","volume":"23","author":"R Kath","year":"2000","unstructured":"Kath R, H\u00f6ffken K, Merkle K (2000) Prevention of immunological complications in bendamustine treatment [abstract]. Onkologie 23:171","journal-title":"Onkologie"},{"key":"1317_CR45","first-page":"R147","volume":"124","author":"HK Heck","year":"1998","unstructured":"Heck HK, Preiss JM, Schmidt P (1998) Bendamustine (B) and mitoxantrone (M) in the treatment of low grade non-Hodgkin\u2019s lymphoma (NHL) [abstract]. J Cancer Res Clin Oncol 124:R147","journal-title":"J Cancer Res Clin Oncol"},{"key":"1317_CR46","first-page":"406","volume":"20","author":"C Kahl","year":"1997","unstructured":"Kahl C, Herold M, H\u00f6ffkes H et al (1997) Bendamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high grade non-Hodgkin\u2019s lymphoma. Onkologie 20:406\u2013408","journal-title":"Onkologie"},{"issue":"3","key":"1317_CR47","first-page":"132","volume":"10","author":"U K\u00f6nig","year":"1999","unstructured":"K\u00f6nig U, Junghass C, Decker S et al (1999) Response of refractory and relapsed low grade non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride-containing regimen [abstract]. Ann Oncol 10(3):132","journal-title":"Ann Oncol"},{"issue":"3","key":"1317_CR48","first-page":"125","volume":"10","author":"K Ruffert","year":"1999","unstructured":"Ruffert K (1999) Therapy of low grade non-Hodgkin\u2019s lymphoma (NHL) with bendamustine and oral etoposide [abstract]. Ann Oncol 10(3):125","journal-title":"Ann Oncol"},{"key":"1317_CR49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","volume":"132","author":"M Herold","year":"2006","unstructured":"Herold M, Schulze A, Niederwieser D et al (2006) Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 132:105\u2013112","journal-title":"J Cancer Res Clin Oncol"},{"key":"1317_CR50","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1080\/1042819042000223822","volume":"45","author":"M K\u00f6nigsmann","year":"2004","unstructured":"K\u00f6nigsmann M, Knauf W, Herold M et al (2004) Fludarabine and bendamustine in refractory and relapsed indolent lymphoma\u2013a multicenter phase I\/II trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma 45:1821\u20131827","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"1317_CR51","first-page":"644","volume":"22","author":"R Weide","year":"1999","unstructured":"Weide R, Heymanns J, K\u00f6ppler H (1999) Successful treatment of alkylating agent resistant low grade B-cell non Hodgkin\u2019s lymphomas with bendamustine\/mitoxantrone\/rituximab (BMR) [abstract]. Onkologie 22(Suppl 1):644","journal-title":"Onkologie"},{"key":"1317_CR52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/10428190290006107","volume":"43","author":"R Weide","year":"2002","unstructured":"Weide R, Heymanns J, Gores A et al (2002) Bendamustine, mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma. 43:327\u2013331","journal-title":"Leuk Lymphoma."},{"key":"1317_CR53","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","volume":"45","author":"R Weide","year":"2004","unstructured":"Weide R, Pandorf A, Heymanns J et al (2004) Bendamustine\/Mitoxantrone\/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 45:2445\u20132449","journal-title":"Leuk Lymphoma"},{"key":"1317_CR54","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/10428190701361828","volume":"48","author":"R Weide","year":"2007","unstructured":"Weide R, Hess G, K\u00f6ppler H et al (2007) High anti\u2013lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 48:1299\u20131306","journal-title":"Leuk Lymphoma"},{"key":"1317_CR55","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low\u2013grade non Hodgkin\u2019s lymphoma. J Clin Oncol 23:3383\u20133389","journal-title":"J Clin Oncol"},{"key":"1317_CR56","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:4473\u20134479","journal-title":"J Clin Oncol"},{"key":"1317_CR57","unstructured":"Mathias JR, Norbert N, Georg M, Andre B, Ulrich von G, Christoph L, Gerhard H, Manfred W, Christina B, Ulrich K, Harald B, Eckhart W, Heinz AD, Dorothea K-K, Fritz R, Juergen B, Dieter H, Axel H, Wolfram B (2009) Bendamustine Plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 114:405"},{"key":"1317_CR58","first-page":"568","volume":"98","author":"HH Kirchner","year":"2001","unstructured":"Kirchner HH, Gaede B, Steinhauer EU et al (2001) Chemoimmuno-therapy with Fludarabine, Bendamustine and Rituximab for relapsed low grade malignant non-Hodgkin\u2019s lymphoma [abstract]. Blood 98:568","journal-title":"Blood"},{"issue":"4","key":"1317_CR59","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2147\/TCRM.S3158","volume":"4","author":"R Weide","year":"2008","unstructured":"Weide R (2008) Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin\u2019s lymphoma. Ther Clin Risk Manag 4(4):727\u2013732","journal-title":"Ther Clin Risk Manag"},{"key":"1317_CR60","doi-asserted-by":"crossref","unstructured":"Moosmann P, Heizmann M, Kotrubczik N, Wernli M, Bargetzi M (2009) Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma [Epub ahead of print]","DOI":"10.3109\/10428190903275602"},{"key":"1317_CR61","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/JCO.2008.21.7695","volume":"27","author":"J Matous","year":"2009","unstructured":"Matous J, Letzer J, Rosen P, Noga S, Fowler N, Smith S, Amin B, Shi H, Parasuraman S, Cheson B (2009) Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study. J Clin Oncol 27:15s (suppl; abstr 8550)","journal-title":"J Clin Oncol"},{"key":"1317_CR62","unstructured":"NCT00864942. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00864942?term=bendamustine&rank=9"},{"key":"1317_CR63","unstructured":"NCT00987493. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00987493?term=bendamustine&rank=38"},{"key":"1317_CR64","unstructured":"NCT00880815. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00880815?term=bendamustine&rank=4"},{"key":"1317_CR65","unstructured":"NCT00901927. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00901927?term=bendamustine&rank=2"},{"key":"1317_CR66","unstructured":"NCT00877006. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00877006?term=bendamustine&rank=33"},{"key":"1317_CR67","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood.V108.11.2710.2710","volume":"108","author":"RH Jagt Van der","year":"2006","unstructured":"Van der Jagt RH, Cohen P, Cheson BD et al (2006) Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin\u2019s lymphoma [abstract]. Blood 108:2710","journal-title":"Blood"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1317-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1317-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1317-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T15:18:08Z","timestamp":1591197488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1317-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,8]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1317-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,8]]}}}